MDBH

• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes • PatentVest's report reveals how combination therapy IP, body-composition optimization, and strategic acquisitions may shape the next phase of obesity therapeutics Dallas, Texas, June 04, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, "The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity" This comprehensive study provides a strategic analysis of the emerging muscle-preservation category developing alongside obesity therapies. The releas

Addison, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC (NASDAQ:MDBH) today announced that its CEO & Co-Founder, Chris Marlett, will present live at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17, 2026 at 2:00 p.m. ET / 11:00 a.m. PT at the Bellagio Resort & Hotel in Las Vegas, Nevada. Marlett will provide an overview of MDB's unique public venture capital model built to provide rational capital for founders of early-stage, category defining companies and asymmetric upside with public market liquidity for investors. Live Webcast: Watch Chris Marlett Presentation. Additionally, PatentVest, MDB's wholly-owned subsidiary and the first integrated IP

· New case study highlights how PatentVest helped Docana navigate a complex AI patent landscape through freedom-to-operate analysis, competitive intelligence, and strategic IP positioning. · The launch introduces a new Case Studies section on the PatentVest website focused on real-world examples of strategic IP leadership and innovation management. Dallas, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announced the launch of a new Case Studies section on its website, beginning with a featured engagement with Docana, an artificial intelligence company operating within a rapidly evolving LLM-related patent environment. The c

10-Q - MDB Capital Holdings, LLC (0001934642) (Filer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

3 - MDB Capital Holdings, LLC (0001934642) (Issuer)

· Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms. · PatentVest's report reveals how intellectual property strategy, receptor-ratio engineering, and delivery platforms may determine the next leaders in obesity therapeutics. DALLAS, TX, May 08, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, "The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market." This comprehensive study provides a strategic analysis of the rapidly evolving ob

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse: "The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery." In April 2026, Eli Lilly's retatrutide delivered 28.7% mean weight loss, the first non-surgical therapy to match bariatric outcomes. But the milestone didn't end the race. It changes it. Everyone is focused on the 28.7%," said Will Rosellini - Chief IP Officer at PatentVest."But that number is just the entry point. Once the mechanism works, the question shifts from who can build it to who controls it, and that's where most teams are underprepared." Across the landscape: No

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

3 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

Addison, TX, March 31, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-defining disruptive technology companies, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025. More Detailed Information 2025 Annual Shareholder Letter HERE. Form 10-K HERE. Key Assets and Strategic Developments eXoZymes (NASDAQ:EXOZ): MDB holds approximately 4.1 million shares and warrants, valued at approximately $30 million based on March 30, 2026 market prices. The company is advancing cell-free biomanufacturing with large, ownable opportunities and clear commercialization

Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse report, "The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine." The report provides a comprehensive analysis of the rapidly evolving amylin drug landscape, a mechanism once considered commercially unviable that is now at the center of global pharmaceutical strategy. Over the past eighteen months, more than $19 billion in deal value has been committed across the amylin space, with major pharmaceutical companies, including Novo Nordisk, Eli Lilly, Roche, Pfizer, and AbbVie, actively building positions. The report highlights

10-K - MDB Capital Holdings, LLC (0001934642) (Filer)

Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced a new addition to its IP Legal Insights section on the company website, a platform dedicated to sharing expert legal perspectives on intellectual property strategy, emerging technology, and innovation-driven industries. The IP Legal Insights section serves as a resource for founders, executives, and investors seeking to better understand how intellectual property decisions impact innovation, competitive positioning, and long-term business value. Through this platform, PatentVest's legal and technical experts provide analysis on key patent law developments, practical prosecution strategies, and emerging trends shapin

Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest, a leading provider of IP Strategy and Legal services, today announced a strategic engagement with Life Seal Vascular and disclosed that it has accepted equity in the company as partial consideration for its services. The arrangement reflects PatentVest's conviction in Life Seal Vascular's underlying technology and its potential to reshape the vascular device market. Life Seal Vascular joins a portfolio of life sciences and medtech clients leveraging PatentVest's proprietary IP platform to map competitive IP landscapes, that identify patenting opportunities and risks, and inform strategic decision-making across R&D, licensing, and

Addison, TX, March 23, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing the results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and may be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for

Dallas, TX, March 11, 2026 (GLOBE NEWSWIRE) -- PatentVest announced the completion of a strategic intellectual property engagement with Porosome Therapeutics, Inc., a biotechnology company developing a first-in-class therapeutic platform designed to restore cellular secretion mechanisms. The collaboration focused on evaluating and strengthening Porosome Therapeutics' intellectual property portfolio to support future partnerships, commercialization efforts, and capital strategy initiatives. PatentVest conducted a comprehensive IP portfolio audit, global patent landscape analyses, competitive benchmarking, and strategic partner assessment. Porosome Therapeutics is advancing Porosome Recons

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, "The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron." As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remaining 95%. Clinical efficacy across leading programs is converging in the 12–16% weight-loss range. In this increasingly competitive field, long-term differentiation depends not only on clinical performance but also on the strength and defensibility of each program's patent portfolio. The report

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)